The Prescription Drug User Fee Act (PDUFA) has reshaped how quickly new therapies reach patients since its introduction in 1992. By allowing the U.S. Food and Drug Administration (FDA) to collect fees from industry to support reviews, the law cut drug review times dramatically and helped patients gain faster access to treatments. Now, as PDUFA VIII negotiations begin, policymakers and experts are debating whether reforms are needed to ensure the program remains effective, transparent, and trusted.
Why PDUFA Matters
Before PDUFA, FDA reviews of new drug applications averaged nearly 29 months, creating delays for patients waiting on critical therapies. The introduction of user fees allowed the FDA to hire additional staff and improve processes. Today, standard applications are typically reviewed within 12 months, and priority applications within six months. These faster timelines have supported innovation and provided patients with timely access to life-saving treatments.
Current Concerns
Despite its successes, PDUFA has drawn criticism. In fiscal year 2024, industry-paid user fees accounted for almost half of FDA’s $47 billion budget. Critics argue that this reliance may give the appearance of industry influence. Others note that calls to lower fees could undercut FDA resources, potentially slowing approvals and weakening oversight. The central question remains whether the FDA can balance efficient review timelines with its duty to remain independent and rigorous.
Lessons from the Past
History demonstrates why PDUFA was necessary. During the HIV/AIDS crisis, promising treatments remained in regulatory review for years, worsening outcomes for patients. PDUFA directly addressed those delays by accelerating access. However, speed alone is not enough. Concerns persist around accelerated approvals, where drugs sometimes rely on surrogate endpoints rather than proven patient outcomes. Without strong post marketing commitments, patients may be exposed to therapies that fall short of expectations.
Opportunities for Reform
Experts from Yale University recently argued that the solution is not to dismantle PDUFA, but to reform it. They recommend greater transparency in negotiations, which often take place between FDA and industry behind closed doors. Involving public stakeholders more directly could help strengthen trust in the system.
Another area for improvement is oversight of accelerated approvals. While these pathways give patients faster access to potentially transformative drugs, they can also leave gaps in evidence. Requiring timely completion of postmarketing studies and prioritizing patient-centered outcomes—such as improved daily functioning—could help ensure that speed does not come at the expense of quality.
Implications for Patients and Industry
For patients, reforms could ensure that treatments remain both accessible and trustworthy. For industry, a more transparent and predictable process could bolster public confidence in FDA approvals. And for regulators, reforms would help maintain the delicate balance between efficiency and accountability.
Conclusion
As discussions over PDUFA VIII unfold, the challenge is to preserve the efficiency gains of the past three decades while building greater transparency and public trust. Safe and effective therapies must continue to reach patients without unnecessary delay, but the FDA’s independence cannot be compromised. At EMMA International, we monitor these policy shifts closely and support life science organizations in navigating the evolving regulatory landscape. By anticipating reforms, companies can remain compliant while keeping patient safety and innovation at the forefront.
For more information on how EMMA International can assist, visit www.emmainternational.com. Contact EMMA International at (248) 987-4497 or by email at info@emmainternational.com to learn more.
References
Ziaks, T., et al. (2025). Reforming PDUFA. New England Journal of Medicine.
U.S. Food and Drug Administration. (2024). Prescription Drug User Fee Act (PDUFA). Retrieved from https://www.fda.gov
